Alpha-Arbutin Plus Kojic Acid Matches Triple Cream for Melasma, With Less Irritation and Lower Relapse
Melasma is one of the more persistent pigmentation conditions to manage. Hormonal shifts, UV exposure, and even heat can trigger recurrence regardless of how consistent a skincare routine is. Triple combination cream, a prescription formulation combining hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%, has been the dermatological standard for decades.
A 2025 clinical trial directly compared that benchmark to an over-the-counter alternative: alpha-arbutin 5% combined with kojic acid 2%.
Study Design
The split-face randomized controlled trial enrolled 30 adults with facial melasma at a site in Thailand, with 27 completing the study. Mean age was 46.59 years, 85.2% female. Fitzpatrick skin types III and IV each accounted for approximately 48% of participants, a population with stronger pigmentary responses.
Participants applied the AAK (alpha-arbutin + kojic acid) formulation to one side of the face and TCC (triple combination cream) to the other, for 12 weeks, followed by a 4-week post-treatment observation period.
12-Week Outcomes
Melanin Index (MI) changes by week 12:
- AAK group: 286.89 at baseline to 266.77 at week 12 (approximately 7% reduction)
- TCC group: 283.36 at baseline to 241.68 at week 12 (approximately 14.6% reduction)
The difference between groups was not statistically significant (p=0.069). Modified MASI scores, the clinician-assessed pigmentation metric evaluating area and intensity, also showed no significant difference between groups (p=0.344).
Physician Global Assessment did show TCC performing significantly better at weeks 4, 8, and 12. In other words, the visible rate of improvement was faster on the TCC side from the clinician’s perspective.
What Happened After Treatment Stopped
The 4-week post-treatment follow-up reversed the picture in an important way.
- AAK group: MI increased by 29.65 points, not statistically significant (p=0.128)
- TCC group: MI increased by 61.81 points, statistically significant rebound (p=0.004)
mMASI scores also showed greater recurrence severity in the TCC group (p=0.045). The pattern: TCC reduces pigmentation faster and more visibly during treatment, but rebounds more sharply once treatment stops.
Adverse Effect Profile
| Side Effect | AAK | TCC |
|---|---|---|
| Erythema at week 4 | 11.1% mild | 33.3% (mild + moderate) |
| Erythema at week 8 | 11.1% mild | 40.7% mild |
| Stinging at week 4 | 11.1% | 25.9% |
| Stinging at week 8 | 0% | 18.5% |
| Dryness | Lower throughout | Higher throughout |
Neither group reported serious adverse effects such as hypopigmentation, skin atrophy, or telangiectasia. The irritation differential, however, was consistent and meaningful for daily adherence.
Reading the Data
The two compounds work through distinct mechanisms that complement each other. Alpha-arbutin competitively inhibits tyrosinase in melanocytes, slowing melanin synthesis. Kojic acid chelates copper ions to block the same enzyme through a separate pathway. Different inhibition routes applied simultaneously suggest additive or synergistic activity.
The clinical implication depends on context. Prescription triple cream remains appropriate when rapid improvement is needed under dermatological supervision. For long-term maintenance, sensitive skin types, or self-managed care, the alpha-arbutin and kojic acid combination offers comparable efficacy on objective measures, lower day-to-day irritation, and more stable post-treatment behavior.
Both approaches are ineffective without consistent SPF use. Melasma responds to UV exposure regardless of what topicals are applied.
Source
Journal of Cosmetic Dermatology via PMC